Thursday, February 29, 2024 6:45:56 AM
On October 10, 2022, the Company’s Board of Directors approved a recapitalization in the form of a 30-to-1 reverse
split. The certificate of amendment was filed and acknowledged by the state of Nevada on October 12, 2022. In
March 2023, the assigned FINRA examiner allowed the time limit associated with the review of the Company’s
recapitalization request to expire. Therefore, the recapitalization was not approved by FINRA and did not become
effective. The Company’s Board of Director’s elected to not pursue an appeal with FINRA.
On August 10, 2023 the Company’s Board of Director’s voted unanimously to resubmit its request for a
recapitalization in the form of a 30-to-1 reverse split with FINRA. The FINRA filing was submitted to FINRA on
August 15, 2023. As of November 13, 2023, the recapitalization request remains under review by the assigned
FINRA examiner.
Recent PSYC News
- PSYC Begins Business Overhaul Process with Consolidation of 10 Previously Issued Convertible Debentures • InvestorsHub NewsWire • 03/13/2024 11:13:44 AM
- PSYC's CEO Provides Detailed Update on the State of the Company in Newly Released Podcast Recording • InvestorsHub NewsWire • 01/05/2024 01:30:00 PM
- PSYC's CEO to Moderate Panel at The Cannabis & Psychedelics Investment Summit Hosted by Kahner Global • InvestorsHub NewsWire • 11/08/2023 01:30:00 PM
- PSYC's Psychedelic Spotlight to be Media Partner for 2023 reMind Psychedelic Business Forum • InvestorsHub NewsWire • 10/04/2023 12:30:00 PM
- Multi Media Company Announces Acquisition • AllPennyStocks.com • 09/21/2023 02:45:00 PM
- PSYC Acquires Stock Day Media to Help Bolster Revenue Production Capacity • InvestorsHub NewsWire • 08/31/2023 12:30:00 PM
- PSYC Enters Strategic Partnership with Target Media to Help Accelerate Audience and Revenue Growth Opportunities • InvestorsHub NewsWire • 08/29/2023 12:30:00 PM
- PSYC's Psychedelic Spotlight Continues Ascent as a Top-Ranking Multimedia Platform for the Psychedelics Sector • InvestorsHub NewsWire • 06/06/2023 12:30:00 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM